Senior Director, Corporate Counsel (12 month FTC) in London

About the RoleAt OXB, our people are at the heart of everything we do. We’re on a mission to enable life‑changing therapies to reach patients around the world and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Senior Director, Corporate Counsel to join our Legal team on a 12‑month fixed‑term contract. In this role, you will provide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group, enable delivery of its strategy and maintain high standards of legal compliance playing a key part in advancing our mission and making a real difference.ResponsibilitiesAssist CLO and Deputy Co Sec with annual report/interims/corporate updatesAssist with FTSE listing requirements and FCA filingsAssist with Group subsidiary managementAssist with corporate governance compliance with best practiceAssist with management of debt financingAssist with any corporate transactions, to the extent requiredAssist with Data Subject Access RequestsRequirementsQualified solicitor in England and Wales holding a current practising certificate or equivalent professional standingProven post‑qualification experience gained in a leading law firm and/or a complex listed or regulated organisation.UK corporate law expertise with experience in governance, capital markets, M&A, compliance and managing complex legal mattersAbility to translate complex legal and regulatory developments into practical, risk‑based advice and effective organisational controls.About OXBOXB is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies.Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA) into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patient’s cells. This can be achieved either by directly administering the vector to the patient (in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. OXB’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.Why Join Us?Competitive total reward packagesWellbeing programmes that support your mental and physical healthCareer development opportunities to help you grow and thriveSupportive, inclusive, and collaborative cultureState‑of‑the‑art labs and manufacturing facilitiesA company that lives its values: Responsible, Responsive, Resilient, RespectWe want you to feel inspired every dayAt OXB, we’re future‑focused and growing fast. We succeed together through passion, commitment, and teamwork.Ready to Make a Difference?Collaborate. Contribute. Change lives.About Oxford BiomedicaOxford Biomedica is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA) into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patient’s cells. This can be achieved either by directly administering the vector to the patient (in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.
#J-18808-Ljbffr